{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T14:32:22Z","timestamp":1756996342468},"reference-count":6,"publisher":"Oxford University Press (OUP)","issue":"615","license":[{"start":{"date-parts":[[1977,1,1]],"date-time":"1977-01-01T00:00:00Z","timestamp":220924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1977,1,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>A patient is described who developed a poorly differentiated sarcoma after cyclophosphamide was used to treat his rheumatoid arthritis. This case emphasizes the importance ot considering neoplastic disease as a potential hazard associated with the use of immunosuppressive drugs.<\/jats:p>","DOI":"10.1136\/pgmj.53.615.48","type":"journal-article","created":{"date-parts":[[2008,12,29]],"date-time":"2008-12-29T20:39:26Z","timestamp":1230583166000},"page":"48-49","source":"Crossref","is-referenced-by-count":6,"title":["Sarcoma complicating therapy with cyclophosphamide"],"prefix":"10.1093","volume":"53","author":[{"given":"J S","family":"Marks","sequence":"first","affiliation":[{"name":"Rheumatism Research Centre, Manchester Royal Infirmary, and University Department of Pathology , Manchester"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C L","family":"Scholtz","sequence":"additional","affiliation":[{"name":"University Department of Pathology , Manchester"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[1977,1,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(67)92837-1","article-title":"Immunological aspects of malignant disease","volume":"i,","author":"BURNET, F.M.","year":"1967","unstructured":"BURNET, F.M. (1967) Immunological aspects of malignant disease. Lancet, i, 1171.","journal-title":"Lancet"},{"key":"ref_2","first-page":"883","article-title":"COOPERATING CLINICS COMMITTEE OF AMERICAN RHEUMATIM ASSOCIATION","volume":"283","year":"1970","unstructured":"COOPERATING CLINICS COMMITTEE OF AMERICAN RHEUMATIM ASSOCIATION (1970) A controlled trial of cyclophosphamide in rheumatoid arthritis. New England Journal of Medicine, 283, 883.","journal-title":"New England Journal of Medicine; A controlled trial of cyclophosphamide in rheumatoid arthritis"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/bmj.4.5732.420","article-title":"Immunosurveillance and cancer: epidemiological evidence","volume":"4","author":"DOLL, R.; KINLEN, L.","year":"1970","unstructured":"DOLL, R. & KINLEN, L. (1970) Immunosurveillance and cancer: epidemiological evidence. British Medical Journal, 4, 420.","journal-title":"British Medical Journal"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/art.1780170406","article-title":"Chromosome abnormalities from cyclophosphamide therapy in rheumatoid arthritis and progressive systemic sclerosis (scleroderma)","volume":"17","author":"TOLCHIN, S.F.; WINKELSTEIN, A.; RODNAN, G.P.; PAN, S.F.; NANKIN, H.R.","year":"1974","unstructured":"TOLCHIN, S.F., WINKELSTEIN, A., RODNAN, G.P., PAN, S.F. & NANKIN, H.R. (1974) Chromosome abnormalities from cyclophosphamide therapy in rheumatoid arthritis and progressive systemic sclerosis (scleroderma). Arthritis and Rheumatism, 17, 375.","journal-title":"Arthritis and Rheumatism"},{"key":"ref_5","first-page":"49","article-title":"stgraduate Medical Journal","volume":"53","year":"1977","unstructured":"stgraduate Medical Journal (January 1977) 53, 49-50."},{"key":"ref_6","article-title":"Introduction Histiocytic medullary reticulosis (HMR) is a rare disorder with a rapidly progressive course, characterized by wasting, fever and enlargement of liver and spleen. The essential anatomical change is a proliferation of atypical histiocytic cells, mainly in the spleen, liver, lymph nodes and bone marrow and was first reported by Scott and Robb Smith","year":"1939","unstructured":"Introduction Histiocytic medullary reticulosis (HMR) is a rare disorder with a rapidly progressive course, characterized by wasting, fever and enlargement of liver and spleen. The essential anatomical change is a proliferation of atypical histiocytic cells, mainly in the spleen, liver, lymph nodes and bone marrow and was first reported by Scott and Robb Smith (1939)."}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/53\/615\/48\/50184976\/postgradmedj-53-48.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/53\/615\/48\/50184976\/postgradmedj-53-48.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T06:50:00Z","timestamp":1683528600000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/53\/615\/48\/7038296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1977,1,1]]},"references-count":6,"journal-issue":{"issue":"615","published-online":{"date-parts":[[1977,1,1]]},"published-print":{"date-parts":[[1977,1,1]]}},"URL":"https:\/\/doi.org\/10.1136\/pgmj.53.615.48","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1977,1]]},"published":{"date-parts":[[1977,1,1]]}}}